to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage ...

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” ...

Structure Therapeutics Inc. has a one year low of $19.39 and a one year high of $62.74. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -27.57 and a beta of -2.35.

Dolphins in ancient Greece were revered as messengers of the gods and held a divine dimension that has survived through the ...

HIGH POINT, N.C. (AP) — HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $3.6 million in its fourth quarter. On a per-share basis, the High Point, North ...

Vast Therapeutics, a clinical-stage life science company, today announced that the U.S. Food and Drug Administration has ...

On the 21st of March, 1952, mournful shockwaves shook the entire nation with the sudden announcement that the First Prime ...

(TENX) on Tuesday reported a loss of $6.3 million in its fourth quarter. On a per-share basis, the Chapel Hill, North Carolina-based company said it had a loss of 18 cents.

Myosin Therapeutics, Inc. (the “Company”) is advancing its lead compound, MT-125, to treat glioblastoma, the most aggressive brain cancer with an average survival time of only 8 months. MT-125 targets ...